###### Strengths and limitations of this study

-   Prospective, longitudinal cohort study with extensive data on exposure to medications as well as other confounders.

-   Internationally recognised and extensively validated neurodevelopmental outcome measures.

-   Longitudinal statistical analysis making use of multiple outcome measurement.

-   No information on confounding by migraine severity or on dose or formulation of triptan medication.

-   As with all observational studies, cannot rule out unmeasured confounding.

Introduction {#s1}
============

Migraine is a chronic pain condition that affects ∼20% of women of reproductive age.[@R1] [@R2] Treatment options for migraine are primarily pharmacologic and include analgesic medications as well as triptans, which are taken in response to an oncoming migraine episode and act to prevent or shorten the severity or duration of the migraine attack. Triptans are class of serotonin 5-HT~1B~, 5-HT~1D~ and 5-HT~1F~ receptor agonists that act on smooth muscle as well as the trigeminal cervical complex, and are the most common prescription acute migraine medication.[@R3] To date, 10 studies have examined the safety of triptan use during pregnancy, but most of them have focused on pregnancy and very early life outcomes. Triptans have been associated with pre-eclampsia, preterm birth and increased risk of folate-deficient anaemia, but not with major congenital malformations.[@R4] A recent meta-analysis found no increased risk of preterm birth or congenital malformation associated with prenatal triptan exposure but did note an increased risk of spontaneous abortion.[@R8] An additional review of migraine treatment during pregnancy recommends that triptans may be used conservatively in pregnancy if adequate pain relief is not achieved through acetaminophen alone.[@R4]

Despite the plausibility of triptans as a neurodevelopmental teratogen,[@R9] [@R10] studies of the effect of prenatal triptan on childhood neurodevelopment have been sparse. Our previous work found that prenatal exposure to triptans was associated with an increased risk of externalising behaviour in 3-year-old children[@R11] and no associations with motor skills, communication or temperament, after adjustment for migraine severity.[@R12] No prior studies have examined changes in behaviour over time following prenatal exposure to triptans. Since brain development is a dynamic process, examining differences in change over time may yield important insights into the mechanism by which triptans affect the developing brain.

Building on our previous research, this study aims to quantify the effect of triptan use during pregnancy on the differences in neurodevelopment outcomes from 18 to 36 months between children. Among neurodevelopmental outcomes associated with triptan use during pregnancy, we also sought to determine whether timing of triptan exposure (first trimester, second/third trimester) is related to differences in change over time.

Methods {#s2}
=======

Norwegian Mother and Child Cohort Study {#s2a}
---------------------------------------

Between 1999 and 2008, the Norwegian Institute of Public Health invited women to participate in the Norwegian Mother and Child Cohort Study (MoBa).[@R13] Women were invited prior to their first routine ultrasound appointment (gestational weeks 13--17). A total of 108 841 women consented to participate (participation rate 42.7%), with 84.8% of the participants completing the 6-month postpartum questionnaire and 60.2% completing the 36-month postpartum questionnaire.[@R14] [@R15] Written informed consent was obtained from all participants, and the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate approved the study; this analysis was granted an exemption from the University of Massachusetts Medical School Institutional Review Board. Data were taken from the quality-ensured Data V.6, released by MoBa in 2012 and includes all children born before 2009 for whom the age 3 years questionnaire was received by 4 May 2011; these data were linked to the Medical Birth Registry of Norway (MBRN) using participants\' 11-digit personal identification numbers. Details of selection into the study are described in [figure 1](#BMJOPEN2016011971F1){ref-type="fig"}.

![Inclusion and exclusion criteria.](bmjopen2016011971f01){#BMJOPEN2016011971F1}

Exclusion criteria were as follows: infant not born alive, multiple births, major congenital malformations or chromosomal abnormalities, and indication of triptan exposure where we were unable to determine whether the triptan was taken prior to or during pregnancy. In total, 7220 women were excluded. We included 59 468 mother--child dyads with complete outcome data at the 18-month and/or 36-month follow-up. We conducted a complete case analysis in which dyads with missing data on variables thought to be confounders were excluded, leaving an analytic sample of 50 469 women, of which 14 790 had complete outcome data only at 18-month follow-up, 6774 had complete data only at 36 months and 28 905 had complete outcome data at 18 and 36 months. In analyses of timing of triptan exposure, we included only 5484 women with a self-reported history of migraine headache at the first pregnancy questionnaire.

Triptan exposure {#s2b}
----------------

Information on exposure to medications was gathered prospectively from two prenatal (Q1-gestational week 17, Q3-gestational week 30) and one postpartum (Q4--6 months postpartum) questionnaires. Women indicated when they had taken a medication (during the 6 months before pregnancy, during weeks 0--4, 5--8, 9--12 and/or 13 or later for Q1, during weeks 13--16, 17--20, 21--24, 25--28 and/or 29 or later for Q3, and from week 30 until birth for Q4) and to write the name of the medication in a text box. Medications were classified according to the WHO Anatomical Therapeutic Chemical (ATC) Classification System.[@R16] The ATC code N02CC was used to determine triptan exposure. Triptan medications were further classified into specific compounds: N02CC01 (sumatriptan), N02CC02 (naratriptan), N02CC03 (zolmitriptan), N02CC04 (rizatriptan), N02CC05 (almotriptan), N02CC06 (eletriptan) and N02CC07 (frovatriptan). No information was available on formulation or dose.

Information on migraine was gathered prospectively from pregnancy questionnaire 1, which asked whether the woman had migraine within 6 months prior to pregnancy or during pregnancy, up to week 17 of pregnancy. Four exposure groups were created: prenatal triptan exposure, prepregnancy triptan use, migraine only and population comparison.

Neurodevelopmental Outcomes {#s2c}
---------------------------

### Child Behavior Checklist {#s2c1}

The Child Behavior Checklist (CBCL) is a validated measure of child behaviour widely used in clinical and research practice; a shortened version, validated in a Norwegian population, was used in MoBa.[@R17] The externalising ('attention problems' and 'aggressive behaviour' subscales) and internalising ('emotionally reactive', 'anxious/depressed' and 'somatic symptoms' subscales) domains were used. Standardised z-scores over or equal to 1.50 on the CBCL measure were used as a clinically relevant cut-off as recommended by Achenbach and Ruffle.[@R18] [@R19] Children scoring over this cut-off had behavioural problems (externalising or internalising) more extreme than 94% of the sample.

### Emotionality, Activity and Shyness Temperament Questionnaire {#s2c2}

The Emotionality, Activity and Shyness Temperament Questionnaire (EAS) measures four temperament domains (emotionality, shyness, sociability and activity). A substantial body of literature has linked early-childhood temperament to later-life depression and other psychiatric diagnoses.[@R20] [@R21] The shortened version of the EAS used in the MoBa study was developed with Norwegian social norms in mind and includes 12 descriptions (eg, "Your child likes to be with people"; "Your child cries easily"), and parents are asked to rate how well each statement applies to their child; in a Norwegian sample, internal consistency (α) within each scale ranged from 0.48 to 0.79.[@R22] We calculated z-scores based on the sample distribution of each domain. Higher z-scores indicate greater parental endorsement of each temperament trait (eg, more shy or more sociable) relative to parental reports of other children in the sample. We additionally categorised scores to indicate temperamental traits more extreme than 94% of the sample (z-score ≥ 1.50).

### Ages and Stages Questionnaire {#s2c3}

The Ages and Stages Questionnaire (ASQ) is a parent-completed questionnaire appropriate for children aged from 4 months to 5 years. Deficits detected by the ASQ are predictive of school difficulties in older children,[@R23] and fine motor skills are highly predictive of later academic achievement.[@R24] The abbreviated ASQ used in MoBa includes questions about developmental milestone attainment in three major categories: gross motor, fine motor, and communication; this shortened version has been validated in a Norwegian population and had excellent test--retest reliability and agreement between parents and professional examiners.[@R25] Scores on the ASQ domains were highly skewed; to address this, we categorised children at each time point as having problems in a given domain if they scored at or above the 94th centile in the sample, versus scoring below the 94th centile. This categorisation is comparable to using a z-score of ≥1.50 as a cut-off.

The CBCL, EAS and ASQ have all been validated in children as young as 18 months. Complete information on the neurodevelopmental outcomes used in this study, including procedures used for validation in the MoBa cohort, and the questions selected for each instrument, are available online.[@R26]

Concomitant medication use {#s2d}
--------------------------

We examined other pain medications and psychotropic medications as potential confounders, acetaminophen, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, benzodiazepines and anti-epileptics. All comedications were categorised as ever versus never used in pregnancy and prior to pregnancy.

Maternal characteristics {#s2e}
------------------------

Maternal age, prepregnancy body mass index (BMI) (underweight or \<18.5 kg/m^2^, normal weight or 18.5--25 kg/m^2^, or overweight, \>25 kg/m^2^ according to WHO guidelines), education (primary or secondary vs university or higher), marital status (married or cohabiting vs other), parity (multiparous vs primiparous) and depression history (yes or no) were all ascertained by self-report on Q1. Maternal depressive and anxiety symptoms were measured by a validated short version of the Hopkins Symptom Checklist (SCL).[@R27] Smoking (ever during pregnancy vs not during pregnancy) and alcohol use (ever during pregnancy vs not during pregnancy) were ascertained by combining information from self-report as well as linkage to the MBRN.

Loss to follow-up {#s2f}
-----------------

We observed substantial loss to follow-up at the 18-month and 36-month questionnaires (57.3% present at 18 and 36 months, 29.3% at 18 months only and 13.4% at 36 months only). To adjust for the potential for selection bias due to measured predictors of attrition, we constructed stabilised inverse probability of censoring weights (IPCW) and conducted weighted analyses.[@R28]

Data analysis {#s2g}
-------------

The purpose of this analysis was to examine differences in neurodevelopmental changes over time associated with prenatal triptan exposure. First, we examined descriptive statistics across the four main exposure groups and compared absolute percentages (for categorical measures); we considered a difference of \>5% to be meaningful. Next, we used generalised estimating equations (GEE) to fit generalised linear models, specifying a binomial distribution and a log link, that included fixed effects for exposure group (prenatal triptan exposure, prepregnancy triptan use, migraine only and population comparison), time (18 and 36 months) and their interaction. GEE models were selected for their approach to missing outcome data (using all available observations, rather than casewise deletion for observations present only at a single time point), as well as their ability to model covariation using flexible covariance structures among repeated measures. Based on comparisons between the empirical and model-based covariance matrices, we selected an exchangeable covariance structure for all models. The resulting estimates represent the change in risk (r-RR) of having a clinically meaningful neurodevelopmental outcome between 18 and 36 months of age for children with prenatal triptan exposure, relative to each contrast group (prepregnancy triptan use only, migraine only and population comparison), with 95% CIs calculated using robust SEs. Models were adjusted for maternal characteristics (age, prepregnancy BMI, parity, marital status, education, smoking or alcohol use in pregnancy, depression symptom severity) and concomitant medication use (NSAIDs, acetaminophen, opioids, antidepressants). To assist in the interpretation of the data, we used model-based predicted probability of outcome at 18 and 36 months to create line graphs of the change in outcome over time for each exposure group. Examination of graphs was useful because the r-RR of \>1 could be a result of qualitatively different phenomena (eg, greater increased risk over time in triptan group relative to increased risks observed in the contrast group, increased risk in the triptan users group and decreased risk in the comparison group).

Finally, for the neurodevelopmental outcomes that were associated with any triptan use during pregnancy, we developed marginal structural models (MSM) to understand the effect of exposure timing on the difference in change of the outcome from 18 to 36 months. We fit MSM with stabilised inverse probability of treatment weights (IPTW) to adjust for measured confounding by baseline characteristics (maternal age, prepregnancy BMI, sociodemographic variables), time-invariant predictors (smoking and alcohol use during pregnancy, folate supplementation, maternal depression severity) as well as time-varying confounders (other medication use, including acetaminophen, NSAIDs, opioids and antidepressants). The MSM approach results in unbiased effect estimates under assumptions of exchangeability and positivity, and allows for appropriate adjustment for the effects of confounders that are also mediators.[@R29] [@R30] We created the IPTW via logistic regression at each exposure time point (prepregnancy, first trimester, second/third trimester) created an IPTW equal to the product of the weight from each time point. The product of IPTW and IPCW was used as the total MSM weight, to account for measured confounding and loss to follow-up. Weighted GEE models were then fit within the migraine-only group. Results are given as the change in risk ratio over time (r-RR) for triptan exposure at each time point (prepregnancy, first trimester, second/third trimester) relative to no exposure during that time, with 95% CIs estimated using robust SEs to account for clustering induced by weighting. For analyses conducted in the first and second steps, we interpreted a significant time-by-group interaction (95% CI that did not include 1) to be indicative of a difference in change between exposure groups, from 18 to 36 months of follow-up.

Results {#s3}
=======

This study included 50 469 women, of whom 1.0% reported using a triptan at least once during pregnancy, 2.0% used triptans prior to pregnancy only and 8.0% had a history of migraine with no use of triptans. Among the 5484 women with history of migraine (10.9% of the total sample), 27.1% used triptans prior to pregnancy, 6.9% reported use during the first trimester and 3.1% reported use during the second or third trimester.

Women who reported triptan use during pregnancy differed little from comparison groups in demographic characteristics; age, prepregnancy BMI, parity, educational attainment, smoking during pregnancy and folate supplementation were similar across groups. However, women who used triptans during pregnancy had higher depression and anxiety symptom scores than women who discontinued triptan use (0.16 vs 0.03). In addition, women with triptan use during pregnancy were more likely to use other medications at higher rates during pregnancy compared to women who discontinued triptan use, including opioids (13.3% vs 4.6%), acetaminophen (78.2% vs 69.8%) and NSAIDs (22.0% vs 10.1%) ([table 1](#BMJOPEN2016011971TB1){ref-type="table"}).

###### 

Maternal and pregnancy characteristics

                                                      Migraine      No migraine                 
  --------------------------------------------------- ------------- ------------- ------------- ---------------
  Age in years (mean, SD)                             30.9 (4.3)    30.4 (4.1)    30.2 (4.5)    30.3 (4.4)
  BMI (kg/m^2^) (N, %)                                                                          
   \<18.5                                             12 (2.4)      25 (2.5)      145 (3.6)     1216 (2.7)
   18.5--25                                           307 (62.0)    608 (60.7)    2491 (61.5)   29 747 (66.2)
   \>25                                               176 (35.6)    369 (36.8)    1414 (34.9)   13 959 (31.1)
  Multiparous                                         254 (51.3)    467 (46.6)    2204 (54.4)   24 467 (54.5)
  Married or cohabitating                             474 (95.8)    980 (97.8)    3922 (96.8)   43 761 (97.4)
  Mother education                                                                              
   Primary or secondary                               165 (33.3)    339 (33.8)    1533 (37.9)   14 511 (32.3)
   University or higher                               330 (66.7)    663 (66.2)    2517 (62.2)   30 411 (67.7)
  Smoking during pregnancy                            57 (11.5)     118 (11.8)    552 (13.6)    5236 (11.7)
  Alcohol during pregnancy                            95 (19.2)     146 (14.6)    623 (15.4)    7506 (16.7)
  Folate supplementation                              299 (60.4)    618 (61.7)    2359 (58.3)   26 462 (58.9)
  Multivitamin supplementation                        186 (37.6)    426 (42.5)    1610 (39.8)   16 661 (37.1)
  Migraine preventive therapy                         8 (1.6)       21 (2.1)      22 (0.5)      0 (0.0)
  Opioids                                                                                       
   Prepregnancy                                       40 (8.1)      52 (5.2)      208 (5.1)     609 (1.4)
   In pregnancy                                       66 (13.3)     46 (4.6)      188 (4.6)     631 (1.4)
  Acetaminophen                                                                                 
   Prepregnancy                                       233 (47.1)    475 (47.4)    1794 (44.3)   11 474 (25.5)
   In pregnancy                                       387 (78.2)    699 (69.8)    2596 (34.1)   19 331 (43.0)
  NSAIDs                                                                                        
   Prepregnancy                                       109 (22.0)    247 (24.7)    938 (23.1)    4450 (9.9)
   In pregnancy                                       109 (22.0)    101 (10.1)    509 (12.6)    2652 (5.9)
  Antidepressants                                                                               
   Prepregnancy                                       24 (4.9)      48 (4.8)      158 (3.9)     1042 (2.3)
   In pregnancy                                       11 (2.2)      11 (1.1)      67 (1.7)      426 (1.0)
  Anticonvulsants                                                                               
   Prepregnancy                                       2 (0.4)       7 (0.7)       10 (0.3)      41 (0.1)
   In pregnancy                                       1 (0.2)       3 (0.3)       13 (0.3)      86 (0.2)
  Benzodiazepines                                                                               
   Prepregnancy                                       8 (1.6)       13 (1.3)      38 (0.9)      240 (0.5)
   In pregnancy                                       8 (1.6)       5 (0.5)       19 (0.5)      165 (0.4)
  Maternal depressive/anxiety symptoms\* (mean, SD)   0.16 (1.70)   0.03 (1.84)   0.23 (1.88)   −0.12 (1.63)
  Pre-eclampsia                                       33 (6.7)      47 (4.7)      170 (4.2)     1536 (3.4)
  Small for gestational age†                          35 (7.1)      65 (6.5)      269 (6.6)     2737 (6.1)
  Apgar 5 (\<7)‡                                      7 (1.4)       9 (0.9)       30 (0.7)      415 (0.9)
  Preterm§                                            19 (3.8)      45 (4.5)      193 (4.8)     2026 (4.5)
  Low birth weight¶                                   11 (2.2)      24 (2.4)      108 (2.7)     1047 (2.3)

Numbers given are frequencies and percents, unless otherwise indicated.

\*Average z-score from the SCL; higher positive scores indicate more depressive symptoms.

†Small for gestational age defined as weight below the 10th centile for gestational age.

‡Number and per cent of children with a 5-min Apgar score of \<7.

§Preterm birth defined as birth before the 37th week of gestation.

¶Low birth weight defined as weight at birth below 2500 g, regardless of the gestational age.

BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs; SCL, Symptom Checklist.

The Externalising Behaviours subscale of the CBCL, as well as the Emotionality and Activity subscales of the EAS, describes a set of behaviours characterised by increased activity, aggression and emotional reactivity. Children whose mothers used triptans during pregnancy had substantial increased risk of high emotionality compared to static or decreased emotionality in children whose mothers used triptans only prior to pregnancy (r-RR 2.18, 95% CI 1.03 to 4.53) as well as those with a history of migraine without triptan use (r-RR 2.51, 95% CI 1.27 to 4.90) and a migraine-free population comparison group (r-RR 2.16, 95% CI 1.14 to 2.14) ([table 2](#BMJOPEN2016011971TB2){ref-type="table"}, [figure 2](#BMJOPEN2016011971F2){ref-type="fig"}). When we examined the association of timing of triptan exposure within the group of women with migraine using MSM with inverse probability weights, the r-RR estimate for first trimester exposure relative to no first trimester exposure was 1.54 (95% CI 0.57 to 4.13) and the r-RR estimate for second/third trimester exposure relative to no second/third trimester exposure was 2.41 (95% CI 0.71 to 8.20) ([table 3](#BMJOPEN2016011971TB3){ref-type="table"}). We also observed differences in the rate of change for activity: children with prenatal triptan exposure had lesser decreases in activity from 18 to 36 months, relative to the prepregnancy (r-RR 1.70, 95% CI 1.02 to 2.80), migraine only (r-RR 1.57, 95% CI 1.04 to 2.36) and population comparison (r-RR 1.67, 95% CI 1.14 to 2.14) groups ([table 2](#BMJOPEN2016011971TB2){ref-type="table"}). Examining the association between outcome and timing of exposure revealed that the r-RR estimate for second/third trimester exposure relative to no second/third trimester exposure was 1.37 (95% CI 0.46 to 4.10) ([table 3](#BMJOPEN2016011971TB3){ref-type="table"}). Externalising behaviour in children with prenatal triptan exposure, as measured by the CBCL, remained elevated compared to all contrast groups but did not show evidence of increase or decrease over time ([table 2](#BMJOPEN2016011971TB2){ref-type="table"}, [figure 2](#BMJOPEN2016011971F2){ref-type="fig"}).

###### 

Change in neurodevelopmental outcome from 18 to 36 months: change over time for prenatal triptan exposure, relative to prepregnancy triptan use, migraine only and population comparison

                                       Per cent (18 months )†   Per cent (36 months)   Unadjusted   Multivariable adjusted\*          
  ------------------------------------ ------------------------ ---------------------- ------------ -------------------------- ------ --------------
  *CBCL externalising behaviour*                                                                                                      
  Prenatal triptan use                 11.0                     10.0                                                                  
   Versus prepregnancy triptans only   7.8                      6.5                    1.11         0.70 to 1.73               1.11   0.70 to 1.75
   Versus migraine only                8.1                      7.6                    0.99         0.69 to 1.43               1.00   0.70 to 1.43
   Versus population comparison        7.7                      6.5                    1.11         0.79 to 1.54               1.11   0.79 to 1.54
  *EAS emotionality*                                                                                                                  
  Prenatal triptan use                 3.2                      6.3                                                                   
   Versus prepregnancy triptans only   5.3                      4.7                    2.18         1.03 to 4.57               2.18   1.03 to 4.53
   Versus migraine only                5.1                      3.9                    2.51         1.28 to 4.90               2.51   1.27 to 4.90
   Versus population comparison        5.2                      4.7                    2.18         1.14 to 4.10               2.16   1.14 to 4.10
  *EAS activity*                                                                                                                      
  Prenatal triptan use                 9.2                      8.3                                                                   
   Versus prepregnancy triptans only   9.7                      4.7                    1.68         1.02 to 2.80               1.70   1.02 to 2.80
   Versus migraine only                9.8                      5.3                    1.57         1.05 to 2.34               1.57   1.04 to 2.36
   Versus population comparison        9.8                      5.1                    1.67         1.14 to 2.41               1.67   1.14 to 2.42
  *CBCL internalizing behaviour*                                                                                                      
  Prenatal triptan use                 8.1                      9.5                                                                   
   Versus prepregnancy triptans only   6.2                      10.8                   0.70         0.41 to 1.16               0.69   0.41 to 1.14
   Versus migraine only                8.7                      10.5                   1.01         0.66 to 1.57               1.02   0.66 to 1.57
   Versus population comparison        7.5                      8.1                    1.14         0.75 to 1.72               1.12   0.74 to 1.70
  *EAS shyness*                                                                                                                       
  Prenatal triptan use                 4.9                      12.3                                                                  
   Versus prepregnancy triptans only   3.5                      9.6                    0.93         0.53 to 1.65               0.92   0.52 to 1.63
   Versus migraine only                4.0                      7.7                    1.30         0.81 to 2.08               1.30   0.81 to 2.08
   Versus population comparison        4.5                      8.1                    1.40         0.91 to 2.16               1.40   0.91 to 2.16
  *EAS sociability*                                                                                                                   
  Prenatal triptan use                 8.8                      6.3                                                                   
   Versus prepregnancy triptans only   6.8                      6.4                    0.77         0.45 to 1.38               0.78   0.44 to 1.38
   Versus migraine only                9.3                      6.1                    1.12         0.69 to 1.80               1.13   0.70 to 1.82
   Versus population comparison        8.0                      5.7                    1.02         0.65 to 1.62               1.03   0.65 to 1.63
  *ASQ gross motor*                                                                                                                   
  Prenatal triptan use                 1.6                      1.2                                                                   
   Versus prepregnancy triptans only   3.3                      3.0                    0.86         0.23 to 3.20               0.86   0.23 to 3.19
   Versus migraine only                2.3                      3.0                    0.58         0.16 to 2.02               0.58   0.17 to 2.03
   Versus population comparison        2.3                      3.1                    0.55         0.16 to 1.87               0.55   0.16 to 1.88
  *ASQ fine motor*                                                                                                                    
  Prenatal triptan use                 13.9                     9.5                                                                   
   Versus prepregnancy triptans only   11.6                     9.4                    0.84         0.52 to 1.36               0.85   0.52 to 1.37
   Versus migraine only                11.5                     9.2                    0.85         0.56 to 1.28               0.85   0.56 to 1.29
   Versus population comparison        11.8                     10.4                   0.78         0.52 to 1.13               0.77   0.52 to 1.14
  *ASQ communication*                                                                                                                 
  Prenatal triptan use                 3.4                      4.6                                                                   
   Versus prepregnancy triptans only   4.1                      4.5                    1.20         0.55 to 2.64               1.22   0.56 to 2.68
   Versus migraine only                3.8                      5.2                    0.96         0.48 to 1.93               0.97   0.48 to 1.95
   Versus population comparison        4.1                      5.0                    1.09         0.56 to 2.16               1.12   0.57 to 2.19

\*Models are adjusted for maternal age, prepregnancy BMI, parity, marital status, education, smoking or alcohol use during pregnancy, SCL depression/anxiety severity score and concomitant medication use during pregnancy (acetaminophen, opioids, NSAIDs, antidepressants).

†Per cent is the per cent with outcome, respectively, at each measurement (18 and 36 months postpartum): for example, at 18 months, 11% of children with prenatal triptan exposure had externalising symptoms at or above a z-score of 1.50, compared with 7.8% of children whose mothers used triptans prior to pregnancy.

‡r-RR is the group-by-time interaction coefficient from the generalised estimating equation model; it is the difference in change from 18 to 36 months for prenatal triptan exposure, relative to each contrast group.

ASQ, Ages and Stages Questionnaire; BMI, body mass index; CBCL, Child Behaviour Checklist; EAS, Emotionality, Activity and Shyness Temperament Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; r-RR, ratio of risk ratios; SCL, Symptom Checklist.

###### 

Change in neurodevelopmental outcome from 18 to 36 months: change over time associated with timing of triptan exposure, within migraine-only sample (N=5484)

                                 Per cent (8 months)†   Per cent (36 months)   Unadjusted   MSM\*                 
  ------------------------------ ---------------------- ---------------------- ------------ -------------- ------ --------------
  CBCL externalising behaviour                                                                                    
   Prepregnancy                  8.4                    7.5                    0.94         0.67 to 1.30   0.90   0.64 to 1.25
   First trimester               11.6                   11.1                   1.16         0.73 to 1.86   1.01   0.56 to 1.80
   Second/third trimester        10.7                   9.8                    0.96         0.48 to 1.91   0.50   0.17 to 1.48
  EAS emotionality                                                                                                
   Prepregnancy                  4.7                    4.7                    1.07         0.69 to 1.67   1.07   0.68 to 1.67
   First trimester               3.8                    5.6                    1.43         0.58 to 3.51   1.54   0.57 to 4.13
   Second/third trimester        4.0                    7.1                    1.52         0.48 to 4.85   2.41   0.71 to 8.20
  EAS activity                                                                                                    
   Prepregnancy                  9.6                    5.7                    0.90         0.63 to 1.28   0.88   0.61 to 1.28
   First trimester               9.3                    8.9                    1.56         0.90 to 2.71   1.98   0.90 to 4.34
   Second/third trimester        9.4                    10.7                   1.56         0.76 to 3.21   1.37   0.46 to 4.10

\*Per cent is the per cent with outcome at each measurement (18 and 36 months postpartum), among those with exposure at each time point (eg, per cent with externalising problems at 18 months with prenatal triptan use={(75/1002)×100}=7.49%. Windows of triptan exposure are not mutually exclusive).

†r-RR is the group-by-time interaction coefficient from the generalised estimating equation model; it is the difference in change from 18 to 36 months for each group, relative to no exposure during that time point.

‡Models are weighted by the product of stabilised IPCW and IPTW; IPCW is the probability of dropout, conditional on maternal age, prepregnancy BMI, marital status, parity, migraine history and use of triptans prior to and during pregnancy. IPTW includes baseline covariates (maternal age, prepregnancy BMI, sociodemographic variables), time-invariant predictors (smoking and alcohol use during pregnancy, folate supplementation, maternal depression severity), time-varying concomitant medication use (acetaminophen, NSAIDs, opioids, antidepressants) and treatment history (triptan use).

BMI, body mass index; CBCL, Child Behaviour Checklist; EAS, Emotionality, Activity and Shyness Temperament Questionnaire; IPCW, inverse probability of censoring weight; IPTW, inverse probability of treatment weight; MSM, marginal structural models; r-RR, ratio of risk ratios.

![Changes from 18 to 36 months for externalising-type behaviours.](bmjopen2016011971f02){#BMJOPEN2016011971F2}

The Internalising Behaviour subscale of the CBCL, along with the Shyness and Sociability subscales of the EAS, describes a set of symptoms characterised by anxiety, shyness and withdrawal. Shyness and sociability were not associated with use of triptans during pregnancy ([table 2](#BMJOPEN2016011971TB2){ref-type="table"}, see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1).

10.1136/bmjopen-2016-011971.supp1

We saw no differences in change of risk for gross motor, fine motor or communication problems from 18 to 36 months for children with prenatal triptan exposure, relative to any comparison group ([table 2](#BMJOPEN2016011971TB2){ref-type="table"}, see online [supplementary figure](#SM1){ref-type="supplementary-material"} S2).

Discussion {#s4}
==========

We observed several neurodevelopmental domains in which change in neurodevelopment was substantially different for children with prenatal triptan exposure, including emotionality and activity; these domains appear to be associated with prenatal triptan exposure specifically, rather than migraine. There were no overall differences in internalising behaviours and shyness and motor problems or communication problems associated with either triptan exposure or migraine.

Our previous work, which was the first to report on neurodevelopmental sequelae of prenatal triptan exposure, indicated that exposed children had higher rates of externalising problems at 36 months than those without prenatal exposure.[@R11] The findings from the current study suggest that these elevated rates of externalising behaviour remain relatively stable between 18 and 36 months; additionally, the observed increases in emotionality and activity describe a consistent profile of temperamental and behavioural dysregulation associated with prenatal triptan exposure. Several studies in the animal literature suggest that 5-HT~1B~ and 5-HT~1D~ receptor expression modifies fetal brain development,[@R10] [@R31] providing a plausible biological mechanism for this observed association.

A possible alternative explanation for our findings is that women who used triptans in pregnancy had the most severe migraine, whereas women who discontinued triptan use prior to pregnancy and women with migraine who did not use triptans had less severe illness. Our prior work found that underlying migraine severity explained some, but not all, of the observed associations,[@R12] and that confounding by migraine severity would have to be very strong to fully explain our findings.[@R11] Therefore, while we cannot rule out confounding by indication, it is unlikely to fully explain these results, which suggest a distinct profile for children with prenatal exposure to triptans in which changes in externalising-type behaviours from 18 to 36 months were markedly different from all comparison groups.

The prevalence of externalising problems among children with prenatal triptan exposure was elevated at 18 months and remained relatively stable at 36 months, while the prevalence of emotionality and activity increased from 18 to 36 months in children with prenatal exposure, compared to all contrast groups. Emotionality, in the context of the Emotionality, Activity and Shyness Questionnaire, includes items that tap emotional reactivity, while items in the Activity subscale ask about higher levels of physical activity. Of potential interest is the fact that the emotionality and activity domains, as well as the externalising behaviour domain, ask parents to report on observable behaviours in their children, such as temper explosions, hyperactivity and coordination problems, whereas the sociability and shyness domains, as well as internalising behaviours, ask parents to report on their child\'s internal state. Parents are better reporters of externalising symptoms, whereas children are better reporters of internalising symptoms.[@R32] Future studies should include replicating these findings in an older cohort of children, in which child self-report and clinical observation of psychological or behavioural problems are available.

The results of this study have important implications for clinicians who may see children born to mothers with migraine headache. Numerous studies have shown that early-childhood emotional and behavioural problems are predictive of academic and emotional difficulties in adolescence,[@R33] but that early intervention can effectively reduce these problems.[@R37] [@R38] Children whose mothers have a history of migraine, and particularly those whose mothers took triptans during pregnancy, may benefit from additional monitoring and potentially, treatment.

There are several important limitations to consider when evaluating the findings from this study. First, MoBa does not collect information on migraine severity, and women with more severe migraine are more likely to use triptans. In our previous research, we carried out sensitivity analyses to examine the potential impact of unmeasured confounding by migraine severity[@R11] as well as using an external validation study to calibrate effect estimates[@R12] to address this source of confounding, and found that migraine severity would have to be an extremely strong confounder to fully explain our results. However, confounding by indication is difficult to control[@R39] and cannot be ruled out as an explanation for the observed results. Second, no information was available on triptan formulation or dose; additionally, we had insufficient power to analyse specific triptans. Triptans have different pharmacokinetic properties and affinities for subclasses of serotonin receptors,[@R40] and considering these medications as a class may elide important information on compound-specific risks. Exposure misclassification is possible; however, it is unlikely to be differential with respect to outcome, and so is more likely to have produced bias towards the null, as has been shown in previous validation studies in the MoBa cohort.[@R41]

These limitations are balanced by important strengths: first, we used advanced analytic methods to appropriately adjust for time-varying confounding by concomitant medication use. Triptan exposure changes over time, and women who use triptans in pregnancy also use many other medications, several of which have previously been associated with neurodevelopmental problems in children.[@R42] Failure to appropriately adjust for these medications may result in incorrectly attributing effects to triptan exposure that are in fact due to other medications. Our study was set in a large, prospective birth cohort with data available on over-the-counter and prescription medication use, allowing for careful consideration of concomitant medication use, as well as other important confounders such as severity of maternal depressive and anxiety symptoms.

This study suggests that prenatal exposure to migraine and triptans may be associated with neurodevelopmental problems in children. However, these findings and our related work are based on a single cohort and should be replicated in other cohorts before clinical recommendations for treatment of migraine in pregnancy are changed.
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